Medi-Mibi (Technetium (99mtc) Sestamibi)

Technetium‑99m sestamibi is a lipophilic cation that enters myocardial cells proportionally to blood flow and binds to mitochondria. The technetium‑99m isotope emits gamma radiation, which is detected by SPECT cameras to create detailed images of myocardial perfusion.

The prescribed dose of Medi-Mibi is determined by the ordering physician based on the specific imaging protocol, patient weight, and clinical indication. Dosing is individualized and should follow established nuclear medicine guidelines.

Safety data for Medi-Mibi in pregnancy and lactation are limited. It should only be used when the potential diagnostic benefit outweighs any possible risk to the fetus or infant, and after careful consideration by the treating physician.

To order Medi-Mibi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

The primary alternative for myocardial perfusion imaging is Thallium‑201. Compared with Thallium‑201, Technetium‑99m sestamibi offers higher photon energy, better image resolution, and a shorter half‑life, which reduces radiation exposure and allows for faster imaging protocols.

Medi-Mibi must be stored refrigerated at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the vial, and use the product within the time frame specified by the manufacturer after removal from cold storage.

Medi-Mibi is administered as an intravenous injection by qualified nuclear medicine personnel. The tracer is typically injected through a peripheral vein, and imaging is performed shortly after administration according to the prescribed protocol.

Serious risks associated with Medi-Mibi include anaphylactic reactions, severe hypotension, and radiation‑induced skin injury. Immediate medical attention is required if any signs of severe allergic response, sudden drop in blood pressure, or unexpected skin changes occur after injection.

Medi-Mibi should be avoided in patients with known hypersensitivity to technetium‑based agents, those with severe renal impairment, and pregnant women unless the diagnostic benefit justifies the potential risk. The prescribing clinician must evaluate each patient’s suitability before administration.